These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 20224465

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resolution of choroidal neovascularization secondary to punctate inner choroidopathy (PIC) with intravitreal anti-VEGF agents: a case series.
    Mangat SS, Ramasamy B, Prasad S, Walters G, Mohammed M, Mckibbin M.
    Semin Ophthalmol; 2011 Jan; 26(1):1-3. PubMed ID: 21275596
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
    Varano M, Tedeschi M, Oddone F, Perillo L, Coppè AM, Parravano M.
    Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy.
    Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ.
    Acta Ophthalmol; 2010 Mar; 88(2):e54-5. PubMed ID: 19489761
    [No Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial.
    Zhang H, Liu ZL, Sun P, Gu F.
    Retina; 2012 Jun; 32(6):1106-13. PubMed ID: 22481479
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of inflammatory choroidal neovascularization (CNV) secondary to punctate inner choroidopathy in a young female of childbearing age with intra-vitreal ranibizumab and half-fluence photodynamic therapy (PDT) - a holistic approach.
    Cornish KS, Lim LT, Imrie F.
    Semin Ophthalmol; 2012 Jun; 27(1-2):29-32. PubMed ID: 22352824
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment.
    Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J.
    Am J Ophthalmol; 2011 Mar; 151(3):529-34. PubMed ID: 21236413
    [Abstract] [Full Text] [Related]

  • 17. Photoreceptor reconstitution correlates with visual improvement after intravitreal bevacizumab treatment of choroidal neovascularization secondary to traumatic choroidal rupture.
    Francis JH, Freund KB.
    Retina; 2011 Feb; 31(2):422-4. PubMed ID: 21240036
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.